Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Small Cell Lung Cancer
Interventions
DRUG

ADI-PEG 20 (Arginine deiminase pegylated)

ADI-PEG 20 was administered intramuscularly (IM) at a fixed dose of 320 IU/m\^2 (36.8 mg/m\^2) once weekly for 4 weeks followed by a 1-week follow-up (1 cycle)

Trial Locations (8)

333

Chang Gung Memorial Hospital - LinKou Branch, Taoyuan District

704

National Cheng Kung University Hospital, Tainan City

10002

National Taiwan University Hospital, Taipei

10065

Memorial Sloan-Kettering Cancer Center, New York

27710

Duke University Medical Center, Durham

B-1200

University Clinic Saint-Luc, Brussels

D-60488

Krankenhaus Nordwest, Frankfurt

EC1A 7BE

St. Bartholomew's Hospital, West Smithfield

All Listed Sponsors
collaborator

Memorial Sloan Kettering Cancer Center

OTHER

collaborator

Duke University

OTHER

collaborator

St. Bartholomew's Hospital

OTHER

collaborator

Krankenhaus Nordwest

OTHER

collaborator

Saint-Luc University Hospital

UNKNOWN

collaborator

National Taiwan University Hospital

OTHER

collaborator

National Cheng-Kung University Hospital

OTHER

collaborator

Chang Gung Memorial Hospital

OTHER

collaborator

Austin Health

OTHER_GOV

collaborator

Polaris Group

INDUSTRY

lead

Ludwig Institute for Cancer Research

OTHER